You, R., Liu, J., Wu, D. B., Qian, X., Lyu, B., Zhang, Y., & Luo, N. (2019). Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China. Cancer Manag Res.

You, Ruxu, Jinyu Liu, David Bin-Chia Wu, XinYu Qian, Boxiang Lyu, Yu Zhang, and Nan Luo. "Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China." Cancer Manag Res 2019.

You, Ruxu, et al. "Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China." Cancer Manag Res 2019.